gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Nuclear DNA content and survival rates of patients with pancreatic cancer: a prospective study on 64 cases

Meeting Abstract

  • corresponding author presenting/speaker Daniel Seehofer - Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Charité Campus Virchow, Berlin, Deutschland
  • Hussian Al-Abadi - Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Charité Campus Virchow, Berlin
  • Jan Langrehr - Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Charité Campus Virchow, Berlin
  • Henning Weidemann - Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Charité Campus Virchow, Berlin
  • Marcus Bahra - Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Charité Campus Virchow, Berlin
  • Hassan Abou-Rebyh - Klinik für Gastroenterologie und Hepatologie, Charité Campus Virchow, Berlin
  • Wilfried Veltzke-Schlieker, - Klinik für Gastroenterologie und Hepatologie, Charité Campus Virchow, Berlin
  • Peter Neuhaus - Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Charité Campus Virchow, Berlin

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO132

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dkk2006/06dkk242.shtml

Veröffentlicht: 20. März 2006

© 2006 Seehofer et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: Nuclear DNA content and pathology are considered to be prognostically relevant to several solid tumors, but controversial findings have emerged from pancreatic carcinoma.

Methods: During the period of 4 years (8/99 –12/ 03) we enrolled a total of 64 patients with histologically proven ductal adenocarcinoma of the pancreas in a prospective study. DNA ploidy was assessed by image cytometry in cytological specimens obtained from ERCP by aspiration and brush cytology.All 64 patients were followed up till death(n=48) or in case of survival(n=16) a mean follow-up period was 12 months.

Results: Median survival rate of all patients affected from pancreatic carcinoma was 13 months. At time of diagnosis, 5% (n=3) of patients presented pT2 carcinoma, 84% (n=54) revealed pT3 tumors und 11% (n=7) showed pT4 tumors. Patients presenting the same tumor stage revealed different ploidy patterns associated with varying surival times Curative resection (RO) of the pancreatic carcinoma could be accomplished in 42% of the cohort while 14% of patients received incomplete resection with remaining tumor cells (R1/2). In addition, further 44% (n=28) of patients were unresectable at time of diagnosis. Histologic grading revealed most frequently poorly differentiated pancreatic carcinoma cells (G3, 48%) while less patients showed moderatly differentiated cacrinoma (G2, 47%) or good differentiated neoplasia (G1, 5%). DNA ploidy was compared to tumor stage (pT), histologic differention (pG) with regard to the clinical course and survival. DNA ploidy was the only significant predictor of survival shown by multivariate analysis.10 out of 17 patients affected from pancreatic carcinoma with diploid or polyploid DNA pattern survived tumor free during the follow up period .In contrast, 44 of 47 patients with aneuploid pancreatic carcinoma experienced tumor recurrence/persitance .The difference of suvival rates between patients with aneuploid versus diploid and polyploid carcinoma was highly significant (p<0,001).

Conclusions: Patients with pancreatic adenocarcinoma will survive longer if their cancer is diploid or tetraploid and will have a very poor prognosis if afflicted with DNA aneuploid cancer.The predictive value of DNA ploidy is present in patients with respectable or unresectable tumor stage.The results maybe helpful for predicting life expectancy, determining treatment strategies and designing future clinical trials.